Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings. METHODS: This non-interventional time and motion study was run in eight countries and 30 day oncology units. Rituximab SC data were collected alongside the MabCute trial (NCT01461928); IV data were collected per routine real-world practice. Trained observers recorded active HCP time for pre-specified tasks (stopwatch) and chair time (time of day). A random intercept model was used to analyze active HCP time (by task and for all tasks combined) in the treatment room and drug preparation area, drug administration duration, chair time and patient treatment room time by country and/or across countries. Active HCP and chair time were extrapolated to a patient's first year of treatment (11 rituximab sessions). RESULTS: Mean active HCP time was 35.0 and 23.7 minutes for IV and SC process, respectively (-32%, p <0.0001). By country, relative reduction in time was 27-58%. Absolute reduction in extrapolated active HCP time (first year of treatment) was 1.1-5.2 hours. Mean chair time was 262.1 minutes for IV, including 180.9 minutes infusion duration, vs. 67.3 minutes for SC, including 8.3 minutes SC injection administration (-74%, p <0.0001). By country, relative reduction was 53-91%. Absolute reduction in extrapolated chair time for the first year of treatment was 3.1-5.5 eight-hour days. CONCLUSIONS: Compared with rituximab IV, rituximab SC was associated with reduced chair time and active HCP time. The latter could be invested in other activities, whereas the former may lead to more available appointments, reducing waiting lists and increasing the efficiency of day oncology units. TRIAL REGISTRATION: ClinicalTrials.gov NCT01200758.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Significant cost savings were also seen in various other countries [7, 8, 44–47].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preparation time or pharmacist time per infusion of rituximab was reported in five publications and ranged from 4–40 min (IV) to 2–20 min (SC) [66, 88, 90, 91, 104].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nineteen publications (seven full publications [52, 66, 88–92] and 12 abstracts [93–104]) reported data on time required, or differences in time required, for IV versus SC rituximab for the treatment of lymphoma (NHL/FL or DLBCL in most publications) (Fig. 2).”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Time savings with SC administration were ~200 min [66, 88, 92, 97].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
In the citing paper
“Similar variations were also seen with studies of rituximab [88]; however, a consistent trend in favor of SC administration was observed across all publications.”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [88]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
McCambridge, J., Witton, J., & Elbourne, D. R. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.08.015 · Cited by 2,748 · cited 1×
“, potential change in HCP behavior because of being directly observed) [20].”
BackgroundPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114 · cited 2×
“Similarly, the SABRINA study showed that rituximab SC shortened administration time to approximately five to seven minutes [11].”
BackgroundMethodDe Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112
Self-citationMonoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma
Fanale, M. A., & Younes, A. (2007) · Drugs · doi:10.2165/00003495-200767030-00002 · Cited by 111
Rituximab: A New Therapeutic Monoclonal Antibody for Non‐Hodgkin's Lymphoma
Scott, S. D. (1998) · Cancer Practice · doi:10.1046/j.1523-5394.1998.006003195.x · Cited by 105
Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2631 · Cited by 98
(2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2006.00789.x · Cited by 89
Rule, S., Collins, G. P., & Samanta, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914033 · Cited by 66 · cited 3×
“This was observed in the UK, where mean pharmacy technician time for rituximab IV was shifted to pharmacist time for rituximab SC, resulting in somewhat higher drug preparation costs for rituximab SC, as a result of higher pharmacist salary [14].”
Background
Research works printed but not linked: 1
- Rummel M, Kim TM, Plenteda C, Capochiani E, Mendoza M, Smith R, et al Patient preference for subcutaneous or intravenous administration of rituximab in previously untreated CD20+ non-Hodgkin lymphoma: interim data from the PrefMab study. Haematologica (EHA annual congress abstracts). 2014; 99:Poster 467.
Cited by
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Sandborn, W. J., Baert, F., Danese, S., Krznarić, Ž., Kobayashi, T., Yao, X., Chen, J., Rosario, M., Bhatia, S., Kisfalvi, K., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.08.027 · Cited by 331
Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154
Chemical and physical instabilities in manufacturing and storage of therapeutic proteins
Krause, M. E., & Şahin, E. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.014 · Cited by 135
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Usmani, S. Z., Nahi, H., Mateos, M., van de Donk, N. W. C. J., Chari, A., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., et al. (2019) · Blood · doi:10.1182/blood.2019000667 · Cited by 126
Erasmus, J. H., Archer, J., Fuerte-Stone, J., Khandhar, A. P., Voigt, E., Granger, B., Bombardi, R. G., Govero, J., Tan, Q., Durnell, L. A., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.011 · Cited by 118
Desai, M. G., Kundu, A., Hageman, M., Lou, H., & Boisvert, D. (2023) · mAbs · doi:10.1080/19420862.2023.2285277 · Cited by 102
Lugtenburg, P., Avivi, I., Berenschot, H., Ilhan, O., Marolleau, J. P., Nagler, A., Rueda, A., Tani, M., Turgut, M., Osborne, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.173583 · Cited by 75
Delgado, S. R., Faissner, S., Linker, R. A., & Rammohan, K. W. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12007-3 · Cited by 76
Subcutaneous drug delivery: An evolving enterprise
Jones, G. B., Collins, D. S., Harrison, M. W., Thyagarajapuram, N. R., & Wright, J. M. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9166 · Cited by 76
Hart, A. L., Panaccione, R., Steinwurz, F., Danese, S., Hisamatsu, T., Cao, Q., Ritter, T. E., Seidler, U. E., Olurinde, M., Vetter, M. L., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.033 · Cited by 75
Subcutaneous drug delivery from nanoscale systems
Tomasini, L., Ferrere, M., & Nicolas, J. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00161-w · Cited by 72
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Klein, C., Jamois, C., & Nielsen, T. G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1822318 · Cited by 70
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology · doi:10.2217/fon-2019-0368 · Cited by 69
Davies, A. J., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P. J., Rule, S. A., Rummel, M., McIntyre, C., Smith, R. B. W., & Badoux, X. C. A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0610-z · Cited by 68
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery
Knowles, S. P., Printz, M. A., Kang, D. W., LaBarre, M. J., & Tannenbaum, R. P. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1981286 · Cited by 58
Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics
Curreri, A. M., Kim, J., Dunne, M., Angsantikul, P., Goetz, M. J., Gao, Y., & Mitragotri, S. (2023) · Advanced Science · doi:10.1002/advs.202205389 · Cited by 42
Kirschbrown, W. P., Wynne, C., Kågedal, M., Wada, R., Li, H., Wang, B., Nijem, I., Črnjević, T. B., Gasser, H., Heeson, S., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1362 · Cited by 40
Hedayati, E., Fracheboud, L., Srikant, V., Greber, D., Wallberg, S., & Linder Stragliotto, C. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211783 · Cited by 39
Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000648 · Cited by 37
Harvey, M. J., Zhong, Y., Morris, E., Beverage, J. N., Epstein, R. S., & Chawla, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261336 · Cited by 36
Filippi, M., Grimaldi, L. M. E., Conte, A., Totaro, R., Valente, M. R., Malucchi, S., Granella, F., Cordioli, C., Morra, V. B., Zanetta, C., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11955-0 · Cited by 30
Flexible care in breast cancer
Wardley, A. M., Canon, J. L., Elsten, L., Murillo, C. P., Črnjević, T. B., Fredriksson, J., & Piccart, M. J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100007 · Cited by 32
O'Brien, G. L., O'Mahony, C., Cooke, K., Kinneally, A., Sinnott, S.-J., Walshe, V., Mulcahy, M., & Byrne, S. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.011 · Cited by 29
Delivery of Community-Based Palliative Care: Findings from a Time and Motion Study
Bhavsar, N. A., Bloom, K., Nicolla, J., Gable, C. L., Goodman, A., Olson, A., Harker, M. J., Bull, J., & Taylor, D. H. (2017) · Journal of Palliative Medicine · doi:10.1089/jpm.2016.0433 · Cited by 29
Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
Jacquot, G., Navarro, P. L., Grange, C., Boudali, L., Harlepp, S., Pivot, X. B., & Detappe, A. (2024) · Advanced Materials · doi:10.1002/adma.202406604 · Cited by 27
DuMond, B., Patel, V., Gross, A., Fung, A., & Weber, S. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221999712 · Cited by 27
Shi, G. H., Connor, R., Collins, D. S., & Kang, D. W. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-020-01880-0 · Cited by 25
Long, M. D., Allegretti, J. R., Danese, S., Germinaro, M., Baker, T., Alvarez, Y., Kavalam, M., Han, C., Jörgens, S., Jiang, L., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00322-x · Cited by 24
Kang, D. W., Bittner, B., Sugarman, B. J., Zepeda, M. L., & Printz, M. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254765 · Cited by 24
Zhang, H., Niu, W., Olaleye, O. E., Du, F., Wang, F., Huang, Y., Yuan, L., Li, Y., Guan-ping, L., Xu, F., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112658 · Cited by 24
Cruz, M. A., Blanco, M. A., & Ekladious, I. (2025) · mAbs · doi:10.1080/19420862.2025.2550757 · Cited by 23
Gibiansky, E., Gibiansky, L. V., Chavanne, C., Frey, N., & Jamois, C. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12665 · Cited by 22
Slavcev, M., Spinelli, A. D., Absalon, E., Masterson, T. J., Heuck, C. J., Lam, A., & Cock, E. D. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s302682 · Cited by 22
George, S., Bourlon, M. T., Overman, M. J., Dixon, M., Shelley, K., Markus, K. J., Kewley, R. M., Pope, S. I., & Albiges, L. K. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102974 · Cited by 21
Waks, A. G., Chen, E., Graham, N., Frey, A., Almeida, K., Attaya, V., Ryding, C., Abbass, I. M., Fung, A., Sussell, J. A., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00021 · Cited by 19
García‐Muñoz, R., Quero, C., Persona, E. P., Domingo‐García, A., Pérez‐López, C., Villaescusa‐de‐la‐Rosa, T., Martínez‐Castro, A. M., Arguiñano‐Pérez, J. M., Parra‐Cuadrado, J. F., & Panizo, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16227 · Cited by 19
Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis
Wallace, Z. S., Harkness, T., Blumenthal, K. G., Choi, H. K., Stone, J. H., & Walensky, R. P. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11133 · Cited by 19
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Freeman, C. L. L., & Sehn, L. H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0748-0 · Cited by 19
Parra, A., Hernandez, C. A., & Prieto‐Pinto, L. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2249232 · Cited by 17
Rog, D. J., Brownlee, W. J., Carod-Artal, F. J., Kalra, S., Barker, N., Lowndes, C., Pendlebury, J., Leclerc, S., Amin, A., Ashton, L., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105380 · Cited by 17
Hebbi, V., Chattopadhyay, S., & Rathore, A. S. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.04.022 · Cited by 16
Kang, D. W., Connor, R., Nekoroski, T., Bitsura, J. A. M., Kindig, S. K., Knowles, S. P., & LaBarre, M. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01883-z · Cited by 15
Sánchez, O. D., Gutierrez, A. M., do Pazo-Oubiña, F., Ginés, J., Martorell, C. N., Vallespir, B. B., Bento, L., García‐Recio, M., & Sampol, A. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s212257 · Cited by 15
A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma
Macdonald, D. A., Crosbie, T., Christofides, A., Assaily, W., & Wiernikowski, J. T. (2017) · Current Oncology · doi:10.3747/co.24.3470 · Cited by 15
Recent landmark studies in follicular lymphoma
Sorigué, M., & Sancho, J. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.03.006 · Cited by 15
Connor, R., Clift, R., & Kang, D. W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2252999 · Cited by 14
Subcutaneous drug delivery devices—Enablers of a flexible care setting
Bittner, B., & Schmidt, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00021-3 · Cited by 14
Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective
Carlson, J., Cox, K., Bedwell, K., & Ku, M. (2015) · International Journal of Nursing Practice · doi:10.1111/ijn.12413 · Cited by 14
Homšek, A., Spasić, J., Nikolić, N., Stanojković, T., Jovanović, M., Miljković, B., & Vučićević, K. M. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221137702 · Cited by 13
Pradelli, L., Massaia, M., Todisco, E., Gherlinzoni, F., Furlan, A., Latargia, M. L., Grande, E., Tripoli, E., Occhipinti, F., Comello, F., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6699 · Cited by 14
Delrue, M., Baylatry, M. T., Joly, A., Corre, E., Marjanovic, Z., Khoury, N., Féger, F., Suner, L., Veyradier, A., Stépanian, A., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26022 · Cited by 13
Yelvington, B. J. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.5.7 · Cited by 13
Rathore, A. S., Metya, S., Sharma, R., & Nitika, N. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115812 · Cited by 12
Hill, S. L., & Davies, A. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0574 · Cited by 12
Body, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3697-5 · Cited by 11
“As such, based on a similar published multi-site study [29], a site effect (i.”
BackgroundSelf-citationEvaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites
Stewart, D. A., Boudreault, J., Maturi, B., Boras, D., & Foley, R. (2018) · Current Oncology · doi:10.3747/co.25.4231 · Cited by 11
Pros and cons of rituximab maintenance in follicular lymphoma
Zhang, L., Ghielmini, M. E. G., Cheson, B. D., & Ujjani, C. S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.007 · Cited by 11
Rule, S. A., Barreto, W. G., Briones, J., Carella, A. M., Casasnovas, O., Pocock, C., Wendtner, C., Zaja, F. F., Robson, S., MacGregor, L., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.274803 · Cited by 10
Self-citationDevelopment pathways for subcutaneous formulations of biologics versus biosimilar development
Zharkov, A., Barton, B., Heinzmann, D., Bakalos, G., & Schreitmüller, T. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1585806 · Cited by 10
Tokuda, J. M., Xie, J., Jawa, V., Hawkins, J. M., Ferbas, J., Joh, N. H., & Joubert, M. K. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.02.001 · Cited by 10
Monfared, A. A. T., Barrows, S., Fox, L., Herbel, B., Herring, W. L., Krumbach, A., & Zhang, Q. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00790-2 · Cited by 9
Cock, E. D., Oskar, S., Lourdudoss, C., Eiras, R., Pietanza, M. C., Arunachalam, A., Alves, G. V., Martinengo, G. L., & Felip, E. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03365-7 · Cited by 9
Delmas, A., Batchelder, L., Arora, I., Bayet, S., Bruhn, D., Eberhardt, A., Philpott, S., & Rodriguez-Leboeuf, A. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1160966 · Cited by 9
Milewski, M., Murashov, M. D., Kapoor, Y., Zhang, J., Zhu, W., Cueto, M. A., & Buist, N. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00132 · Cited by 8
Connor, R., Nekoroski, T., & Kang, D. W. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03116-5 · Cited by 8
Lei, M. M., Li, Q., O’Day, K., Meyer, K. L., Wang, A., & Jun, M. P. (2024) · Future Oncology · doi:10.1080/14796694.2024.2354157 · Cited by 8
Ghosh, C. C., Cournoyer, L., Liu, Y., Ballarin, A., Layman, I. B., LaPorte, J. P., Morrissey, M., Fraser, K., Perati, S., Cox, B. F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008837 · Cited by 8
Lonardi, S., Lugowska, I. A., O’Donnell, A. E., Jackson, C., Latten-Jansen, L. M., North, R. T., Bahleda, R., Garrido, M., Santoro, A., Chacon, M. R., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011918 · Cited by 8
Favier, M., Le Goc-Sager, F., Vincent-Cantini, I., Launay, V., Giroux, E.-A., Lièvremont, K., Bonnet, I., Barbe, C., Duval, E., Loric, N., et al. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.07.014 · Cited by 7
Subcutaneous Administration of Antibody-drug Conjugates
Yaseen, A. A., Rahman, M. A., & Tumey, L. N. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00442-5 · Cited by 7
Ziegengeist, J. L., & Tan, A. R. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.10.005 · Cited by 7
Subcutaneous Administration: Evolution, Challenges, and the Role of Hyaluronidase
Eisenberg, S. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.663-671 · Cited by 7
Ozawa, Y., Hicks, K. C., Minnar, C. M., Knudson, K. M., Schlom, J., & Gameiro, S. R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1915561 · Cited by 6
Nolan, R. P., Kang, D. W., Maneval, D. C., Knowles, S. P., LaBarre, M. J., & Printz, M. A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.062 · Cited by 5
Desai, M. G., Kenney, J., & Pezalla, E. J. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2351165 · Cited by 5
Sazatornil, M. R. A., Arenaza, A., Bayo, J. L., Mata, J. G., de Castro, J. M. G., León, J., Letéllez-Fernández, J., Reguero, V., Chamorro, C. M., & Salar, A. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06277-8 · Cited by 5
Oshi, M., Nakayama, T., Ota, I., Sasamoto, M., Yamada, A., Narui, K., Takabe, K., & Endo, I. (2025) · Breast Cancer · doi:10.1007/s12282-025-01803-6 · Cited by 4
Ressa, R., Ettinger, J., Chowdhury, E., Graham, L., Ndirangu, K., Mancebo, J. Z., & Bodnar, C. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2025.2609499 · Cited by 4
Hakim, M. H., Brindise, M. C., Ahmadzadegan, A., Buno, K., dos Santos, A., Cragg, K. R., Dou, Z., Ladisch, M. R., Ardekani, A. M., Vlachos, P. P., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00240 · Cited by 4
Kyriopoulos, D., Tsiantou, V., Papageorgiou, L., Theodoropoulou, F., & Athanasakis, K. (2017) · Journal of Cancer Therapy · doi:10.4236/jct.2017.88063 · Cited by 4
Predicting Subcutaneous Antibody Bioavailability Using Ensemble Protein Language Models
Cabreza, M., Hojegian, W., Wu, I.-E., & Lai, P. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00523 · Cited by 3
Anglin, P., Elia-Pacitti, J., Eberg, M., Muratov, S., KUKASWADIA, A. A., Sharma, A., & Ewara, E. M. (2023) · Current Oncology · doi:10.3390/curroncol30060418 · Cited by 3
Gao, Y., Zhang, L., Gao, S., Yang, Y., Zhang, Q., Zhang, H., He, P., Li, F., Jing, H., Grange, S., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2439525 · Cited by 3
Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center
Sánchez‐González, B., Torres, E., Ferraro, M. P., Calafell, M., Gale, C., Martínez, L., Sancho, E., Garcia, P., Gimeno, E., García‐Pallarols, F., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1349906 · Cited by 3
Péterlin, P., Guillaume, T., Garnier, A., Bourgeois, A. L., Mahé, B., Dubruille, V., Blin, N., Gallas, P., Touzeau, C., Gastinne, T., et al. (2018) · Leukemia Research Reports · doi:10.1016/j.lrr.2018.01.002 · Cited by 3
Muntañola, A., Arguiñano‐Pérez, J. M., Dávila, J., de Villambrosía, S. G., Carpio, C. D. C., Ubieto, A. J., Salar, A., & ósea), T. G. (. E. D. L. Y. T. D. M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13450 · Cited by 3
Bellone, M., Sabinot, A., D’Arpino, A., Salè, E. O., Ghislieri, D., & Pradelli, L. (2024) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2024.3170 · Cited by 3
Kashiura, D., Souza, P. V., dos Santos, H. P., Nardi, E., Sa, A., Santos, B., & Alves, M. (2018) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v10.n3.p255-61 · Cited by 3
Prosperini, L., Pradelli, L., Santoni, L., Perini, D., Cottone, S., & Vercellino, M. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s501716 · Cited by 2
Tursi, A., Italian Group for Switch of Biologics, Mocci, G., Elisei, W., Savarino, E. V., Maconi, G., Scaldaferri, F., & Alfredo, P. A. P. A. (2024) · Minerva Gastroenterology · doi:10.23736/s2724-5985.24.03712-4 · Cited by 2
Zietse, M., Malmberg, R., van Leeuwen, R. W. F., Thielen, F. W. F., & Groot, C. A. U. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11719-0 · Cited by 2
Connor, R., Blouw, B., Cowell, J., Chen, K., Zhao, C., & Kang, D. W. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00380-0 · Cited by 2
Nehra, J., Bradbury, P. A., Ellis, P. M., Laskin, J. J., Kollmannsberger, C., Hao, D., Juergens, R. A., Goss, G. D., Wheatley‐Price, P., Hotte, S. J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00904-7 · Cited by 1
Boas Práticas na Administração do Rituximab: Revisão Integrativa da Literatura
Rodrigues, C. A., de Lima, M. T. C., & Domenico, E. B. L. D. (2022) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2022v68n3.2194 · Cited by 1
Obinututsumabi follikulaarisen lymfooman ensilinjan hoidossa
Härkönen, U., Heiskanen, J., Hyvärinen, A., & Oravilahti, T. (2018) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
Witkowska, M., Witkowska, S., Klimczak, M., Frydecka, A., Witkowski, M., & Smolewski, P. (2021) · Oncoreview · doi:10.24292/01.or.1222550621
Delrue, M. (2021) · theses.fr (ABES) · doi:10.70675/1be48915z5690z4ef9zaa82z772ac417b6e6
Metadata
- Authors
- De Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T.
- Affiliations
- United BioSource Corporation (United Kingdom) (GB)
- Concordia University (CA)
- Genentech (US)
- Ospedale Policlinico San Martino (IT)
- F. Hoffmann-La Roche AG (CH)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-30
- Volume
- 11
- Issue
- 6
- Pages
- e0157957
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4928781
- OpenAlex
- W2472310215
- Cited by
- 108
- References
- 16
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 15 · 2023: 11 · 2022: 6 · 2021: 13 · 2020: 8 · 2019: 11 · 2018: 10 · 2017: 10 · 2016: 1
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- F. Hoffman-La Roche
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Social Sciences › Decision Sciences › Management Science and Operations Research › Healthcare Operations and Scheduling Optimization
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- rituximab, subcutaneous administration, intravenous infusion, non-Hodgkin lymphoma, treatment efficiency
- MeSH terms
- Rituximab, Antineoplastic Agents, Humans, Infusions, Intravenous, Injections, Subcutaneous, Lymphoma, Non-Hodgkin, Time and Motion Studies, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.